205 related articles for article (PubMed ID: 28052799)
41. A Comparison of Short-Term Growth During Treatment with Two Dry Powder Combinations of Inhaled Corticosteroids and Long-Acting β₂-Agonists.
Wolthers OD; Shah T
J Aerosol Med Pulm Drug Deliv; 2015 Jun; 28(3):182-8. PubMed ID: 25166221
[TBL] [Abstract][Full Text] [Related]
42. Pharmacokinetics, Safety, and Tolerability of a New Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate Diskus(®) in Healthy Adults.
Vutikullird AB; Gillespie M; Song S; Steinfeld J
J Aerosol Med Pulm Drug Deliv; 2016 Apr; 29(2):207-14. PubMed ID: 26624976
[TBL] [Abstract][Full Text] [Related]
43. Comparison of powder and aerosol formulations of salmeterol in the treatment of asthma.
Wolfe J; Kreitzer S; Chervinsky P; Lawrence M; Wang Y; Reilly D; Davis S; Stahl E
Ann Allergy Asthma Immunol; 2000 Mar; 84(3):334-40. PubMed ID: 10752919
[TBL] [Abstract][Full Text] [Related]
44. Efficacy and tolerability of salmeterol/fluticasone propionate versus montelukast in childhood asthma: A prospective, randomized, double-blind, double-dummy, parallel-group study.
Maspero J; Guerra F; Cuevas F; Gutierrez JP; Soto-Ramos M; Anderton S; Mechali D; Chan R; Pedersen S
Clin Ther; 2008 Aug; 30(8):1492-504. PubMed ID: 18803991
[TBL] [Abstract][Full Text] [Related]
45. A 12-week, multicenter, randomized, partially blinded, active-controlled, parallel-group study of budesonide inhalation suspension in adolescents and adults with moderate to severe persistent asthma previously receiving inhaled corticosteroids with a metered-dose or dry powder inhaler.
Murphy K; Noonan M; Silkoff PE; Uryniak T
Clin Ther; 2007 Jun; 29(6):1013-26. PubMed ID: 17692718
[TBL] [Abstract][Full Text] [Related]
46. Comparative efficacy and safety of twice daily fluticasone propionate powder versus placebo in the treatment of moderate asthma.
Pearlman DS; Noonan MJ; Tashkin DP; Goldstein MF; Hamedani AG; Kellerman DJ; Schaberg A
Ann Allergy Asthma Immunol; 1997 Apr; 78(4):356-62. PubMed ID: 9109702
[TBL] [Abstract][Full Text] [Related]
47. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.
Kerwin EM; Gotfried MH; Lawrence D; Lassen C; Kramer B
Clin Ther; 2011 Dec; 33(12):1974-84. PubMed ID: 22177371
[TBL] [Abstract][Full Text] [Related]
48. Comparison of adjustable- and fixed-dose budesonide/formoterol pressurized metered-dose inhaler and fixed-dose fluticasone propionate/salmeterol dry powder inhaler in asthma patients.
Busse WW; Shah SR; Somerville L; Parasuraman B; Martin P; Goldman M
J Allergy Clin Immunol; 2008 Jun; 121(6):1407-14, 1414.e1-6. PubMed ID: 18455221
[TBL] [Abstract][Full Text] [Related]
49. A comparison of the efficacy and tolerability of single doses of HFA 134a albuterol and CFC albuterol in mild-to-moderate asthmatic patients.
Langley SJ; Sykes AP; Batty EP; Masterson CM; Woodcock A
Ann Allergy Asthma Immunol; 2002 May; 88(5):488-93. PubMed ID: 12027070
[TBL] [Abstract][Full Text] [Related]
50. Efficacy of salmeterol xinafoate powder in children with chronic persistent asthma.
Weinstein SF; Pearlman DS; Bronsky EA; Byrne A; Arledge T; Liddle R; Stahl E
Ann Allergy Asthma Immunol; 1998 Jul; 81(1):51-8. PubMed ID: 9690573
[TBL] [Abstract][Full Text] [Related]
51. Easyhaler, a novel multiple dose powder inhaler: clinically equivalent to salbutamol metered dose inhaler and easier to use.
Nieminen MM; Vidgren M; Laurikainen K; Järvinen M; Liippo K; Tammivaara R; Silvasti M
Respiration; 1994; 61(1):37-41. PubMed ID: 8177971
[TBL] [Abstract][Full Text] [Related]
52. A cumulative dose study of levalbuterol and racemic albuterol administered by hydrofluoroalkane-134a metered-dose inhaler in asthmatic subjects.
Tripp K; McVicar WK; Nair P; Corren J; Pleskow WW; Goodwin E; Baumgartner RA; Hanrahan JP
J Allergy Clin Immunol; 2008 Sep; 122(3):544-9. PubMed ID: 18692886
[TBL] [Abstract][Full Text] [Related]
53. Efficacy and safety of budesonide administered by pressurized metered-dose inhaler in children with asthma.
Meltzer EO; Pearlman DS; Eckerwall G; Uryniak T; DePietro M; Lampl K
Ann Allergy Asthma Immunol; 2015 Dec; 115(6):516-22. PubMed ID: 26460293
[TBL] [Abstract][Full Text] [Related]
54. A dose-ranging study of the bronchodilator effects of abediterol (LAS100977), a long-acting β2-adrenergic agonist, in asthma; a Phase II, randomized study.
Singh D; Pujol H; Ribera A; Seoane B; Massana E; Astbury C; Ruiz S; de Miquel G
BMC Pulm Med; 2014 Nov; 14():176. PubMed ID: 25398689
[TBL] [Abstract][Full Text] [Related]
55. Clinical equivalence of a novel multiple dose powder inhaler versus a conventional metered dose inhaler on bronchodilating effects of salbutamol.
Vidgren M; Silvasti M; Korhonen P; Kinkelin A; Frischer B; Stern K
Arzneimittelforschung; 1995 Jan; 45(1):44-7. PubMed ID: 7893268
[TBL] [Abstract][Full Text] [Related]
56. Prospective, open-label assessment of albuterol sulfate hydrofluoroalkane metered-dose inhaler with new integrated dose counter.
Given J; Taveras H; Iverson H; Lepore M
Allergy Asthma Proc; 2013; 34(1):42-51. PubMed ID: 23265285
[TBL] [Abstract][Full Text] [Related]
57. Albuterol via metered-dose inhaler in children: Lower doses are effective, and higher doses are safe.
Muchão FP; Souza JM; Torres HC; De Lalibera IB; de Souza AV; Rodrigues JC; Schvartsman C; da Silva Filho LV
Pediatr Pulmonol; 2016 Nov; 51(11):1122-1130. PubMed ID: 27171324
[TBL] [Abstract][Full Text] [Related]
58. The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients.
Gawchik SM; Saccar CL; Noonan M; Reasner DS; DeGraw SS
J Allergy Clin Immunol; 1999 Apr; 103(4):615-21. PubMed ID: 10200010
[TBL] [Abstract][Full Text] [Related]
59. Indacaterol provides sustained 24 h bronchodilation on once-daily dosing in asthma: a 7-day dose-ranging study.
LaForce C; Alexander M; Deckelmann R; Fabbri LM; Aisanov Z; Cameron R; Owen R; Higgins M
Allergy; 2008 Jan; 63(1):103-11. PubMed ID: 18053019
[TBL] [Abstract][Full Text] [Related]
60. Extended-release albuterol in the treatment of 6- to 12-year-old asthmatic children.
Skoner DP; Boltansky H; Kobayashi RH; Pearlman DS; Shapiro G; Harrison JE; Trochelmann LM; Lorber RR
Ann Allergy Asthma Immunol; 1996 May; 76(5):462-8. PubMed ID: 8630721
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
